Objective: This study’s primary goal is to create a novel, sensitive and comprehensive reverse phase-high performance liquid chromatography (RP-HPLC) procedure. The computation of Imeglimin’s dose and dosage is the primary goal. Method: Chemicals and impurities were separated chromatographically using a C18 (AGILENT) chromatographic column. Methanol and 0.1% OPA are present in the mobile phase in a 40:60 v/v ratio. A 240 nm ultraviolet light detector was employed for the purpose of detection. With a retention time of 4.718 minutes, the results demonstrated the effectiveness of meglimin. After adjusting the flow rate to 0.7 mL/min, there was good separation. There are several imeglimin doses planned, ranging from 10 to 50 μg/mL. 101.46 to 101.12% in yield. Results: This method’s validation has good accuracy, sensitivity, precision, linearity, specificity, and robustness, and it satisfies the requirements of the International Conference on Harmonization. Conclusion: In conclusion, imeglimin was predicted and the construction method was isolated. In conclusion, it’s feasible for daily use.
No takes yet. Share an insight, caveat, or question.
Jahagirdar et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: